Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease
Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease
复制标题
血浆 microRNA-586 是急性移植物抗宿主病的新生物标志物
DOI：
10.1007/s00277-015-2414-z
复制
发表时间：
2015-06
期刊：
影响因子：
--
通讯作者：
Jun Wan
中科院分区：
文献类型：
--
作者：
Meng Lv;Wei Zhang;Xiaojun Huang;Jun Wan
急性移植物抗宿主病（Acute graft-versus-host disease，aGVHD）是异基因造血细胞移植（allo-HSCT）患者发病和死亡的主要原因之一。microRNA（miRs）有可能成为aGVHD的新生物标志物。在这项研究中，我们收集了98例接受allo-HSCT的患者的样本; 63例患者发生了aGVHD，35例患者没有发生。采集52例患者aGVHD前、aGVHD发生时、aGVHD后3个时间点的血浆标本，采用实时荧光定量PCR检测miR-586的表达水平。我们发现，血浆miR-586水平在I-II级aGVHD发作时降低（P= 0.074）。相反，当检测到感染时，血浆miR-586水平增加。此外，我们检测了感染但未发生aGVHD的患者的miR-586表达水平，我们发现miR-586上调（P= 0.005）。我们还比较了aGVHD患者和对照患者移植后第7天的血浆miR-586水平。aGVHD组中miR-586的表达明显高于非aGVHD组（P< 0.05）。当排除感染患者时，两组间差异更显著（P= 0.004）。此外，受试者操作特征（ROC）分析表明，在第7天较高的miR-586表达水平可以预测即将发生的aGVHD。miR-586预测aGVHD的最佳临界值为2200 copies/μL，敏感性为87.5%，特异性为55.0%，曲线下面积（AUC）为0.739（95%CI 0.598- 0.880，P = 0.004）。我们的研究表明miR-586可能参与aGVHD的发生，并可能成为新的aGVHD治疗的假定靶点。异基因造血干细胞移植后第7天血浆中miR-586水平可能是预测aGVHD发生的潜在生物标志物。
Acute graft-versus-host disease (aGVHD) is one of the major causes of morbidity and mortality in patients receiving allogeneic hematopoietic cell transplantation (allo-HSCT). MicroRNAs (miRs) were found to have the potential to be the new biomarkers of aGVHD. In this study, we collected samples from 98 patients who underwent allo-HSCT; 63 patients developed aGVHD, and 35 patients did not. Plasma samples were collected at three time points (before aGVHD, at the onset of aGVHD, and after aGVHD) from 52 patients, and the miR-586 expression level was detected by quantitative real-time PCR. We found that the plasma miR-586 level was decreased at the onset of grade I–II aGVHD (P= 0.074). In contrast, when infections were detected, plasma miR-586 level was increased. Moreover, we detected the miR-586 expression level in patients who had infections but did not have aGVHD, and we found that miR-586 was upregulated (P= 0.005). We also compared the plasma miR-586 level at day 7 after transplantation between aGVHD patients and control patients. In the aGVHD group, there was a considerably higher miR-586 expression in comparison with the non-aGVHD group (P< 0.05). A more significant difference between the two groups was found when the patients with infections were excluded (P= 0.004). Furthermore, receive operating characteristic (ROC) analysis indicated that a higher expression level of miR-586 at day 7 could predict impending aGVHD. The optimal cutoff value of miR-586 to predict aGVHD was 2200 copies/μL with a sensitivity of 87.5 % and specificity of 55.0 %, and the area under the curve (AUC) was 0.739 (95 % CI 0.598–0.880,P= 0.004). Our study suggests that miR-586 might participate in the occurrence of aGVHD and could be a putative target for novel aGVHD therapy. The plasma level of miR-586 at day 7 after allo-HSCT would be a potential biomarker for predicting the occurrence of aGVHD.
登录
查看更多内容
影响因子：
5.5
作者：
S. Zinöcker;L. Sviland;R. Dressel;B. Rolstad
通讯作者：
S. Zinöcker;L. Sviland;R. Dressel;B. Rolstad
影响因子：
20.3
作者：
Hori, Tsukasa;Naishiro, Yasuyoshi;Kokai, Yasuo
通讯作者：
Kokai, Yasuo
DOI：
10.1007/978-3-319-03218-4_36
发表时间：
2016
期刊：
--
影响因子：
--
作者：
H. Gloster;Lauren E. Gebauer;Rachel L. Mistur
通讯作者：
H. Gloster;Lauren E. Gebauer;Rachel L. Mistur
移植物抗宿主病
DOI：
10.1007/978-3-030-04489-3_18
发表时间：
2019
期刊：
Clinical Ophthalmic Oncology
影响因子：
--
作者：
E. Espana;Lauren J. Jeang;Arun D. Singh
通讯作者：
Arun D. Singh
影响因子：
6.5
作者：
Lawrie, Charles H.;Gal, Shira;Harris, Adrian L.
通讯作者：
Harris, Adrian L.